A
Agilent Technologies Inc.

Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide.
Market Cap: 37.8 Billion
Primary Exchange: NEW YORK STOCK EXCHANGE INC.
Website: www.agilent.com
Shares Outstanding: 300 Million
Float: 0
Dividend: 0.806312457617226 (0.01%)
Beta: 1.05088356243598
Sector: Professional, Scientific, and Technical Services
Industry: Testing Laboratories
Ethical Flags

Longest drawdown: 874 trading days
From: 2014-01-22 To: 2017-07-12
Lowest Point:
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
via: Business Wire at 2019-06-11 03:56:00:000
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
via: Business Wire at 2019-06-11 03:56:00:000
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
via: Business Wire at 2019-06-11 03:56:00:000
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|---|---|---|---|---|---|---|---|
2022-07-01 | 2022-07-27 | 2022-07-05 | 2022-05-18 | 0.21 | Cash | |||
2022-04-04 | 2022-04-27 | 2022-04-05 | 2022-02-15 | 0.21 | Cash | |||
2019-09-30 | 2019-10-23 | 2019-10-01 | 2019-09-18 | 0.164 | No Change QoQ | |||
2019-07-01 | 2019-07-24 | 2019-07-02 | 2019-05-22 | 0.164 | No Change QoQ | |||
2019-04-01 | 2019-04-24 | 2019-04-02 | 2019-03-20 | 0.164 | No Change QoQ | |||
2018-12-28 | 2019-01-23 | 2018-12-31 | 2018-11-14 | 0.164 | Increase | |||
2018-10-01 | 2018-10-24 | 2018-10-02 | 2018-09-19 | 0.149 | No Change QoQ | |||
2018-07-02 | 2018-07-25 | 2018-07-03 | 2018-05-16 | 0.149 | No Change QoQ | |||
2018-04-02 | 2018-04-25 | 2018-04-03 | 2018-03-21 | 0.149 | No Change QoQ | |||
2017-12-29 | 2018-01-24 | 2018-01-02 | 2017-11-15 | 0.149 | Increase | |||
2017-10-02 | 2017-10-25 | 2017-10-03 | 2017-09-20 | 0.132 | No Change QoQ | |||
2017-06-29 | 2017-07-26 | 2017-07-03 | 2017-05-17 | 0.132 | No Change QoQ | |||
2017-03-31 | 2017-04-26 | 2017-04-04 | 2017-03-15 | 0.132 | No Change QoQ | |||
2016-12-29 | 2017-01-25 | 2017-01-03 | 2016-11-17 | 0.132 | Increase | |||
2016-09-30 | 2016-10-26 | 2016-10-04 | 2016-09-21 | 0.115 | No Change QoQ | |||
2016-06-30 | 2016-07-27 | 2016-07-05 | 2016-05-18 | 0.115 | No Change QoQ | |||
2016-04-01 | 2016-04-27 | 2016-04-05 | 2016-03-16 | 0.115 | No Change QoQ | |||
2015-12-31 | 2016-01-27 | 2016-01-05 | 2015-11-19 | 0.115 | Increase | |||
2015-09-25 | 2015-10-21 | 2015-09-29 | 2015-09-16 | 0.1 | No Change QoQ | |||
2015-06-26 | 2015-07-22 | 2015-06-30 | 2015-05-20 | 0.1 | No Change QoQ | |||
2015-03-27 | 2015-04-22 | 2015-03-31 | 2015-03-18 | 0.1 | No Change QoQ | |||
2015-01-02 | 2015-01-28 | 2015-01-06 | 2014-11-20 | 0.1 | Decrease | |||
2014-09-26 | 2014-10-22 | 2014-09-30 | 2014-09-17 | 0.132 | No Change QoQ | |||
2019-09-30 | 2019-10-23 | 2019-10-01 | 2019-09-18 | 0.164 | Cash | |||
2019-12-30 | 2020-01-22 | 2019-12-31 | 2019-11-20 | 0.18 | Cash | |||
2020-03-30 | 2020-04-22 | 2020-03-31 | 2020-03-18 | 0.18 | Cash | |||
2020-06-29 | 2020-07-22 | 2020-06-30 | 2020-05-20 | 0.18 | Cash | |||
2020-10-05 | 2020-10-28 | 2020-10-06 | 2020-09-16 | 0.18 | Cash | |||
2021-01-04 | 2021-01-27 | 2021-01-05 | 2020-11-18 | 0.194000005722046 | Cash | |||
2021-04-05 | 2021-04-28 | 2021-04-06 | 2021-03-17 | 0.194 | Cash | |||
2021-07-02 | 2021-07-28 | 2021-07-06 | 2021-05-19 | 0.194 | Cash | |||
2021-10-04 | 2021-10-27 | 2021-10-05 | 2021-09-22 | 0.194 | Cash | |||
2022-01-03 | 2022-01-26 | 2022-01-04 | 2021-11-17 | 0.21 | Cash |
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|